Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2020-07-13
2021-01-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.
NCT04339686
Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections
NCT04357938
Prediction of Clinical Course in COVID19 Patients
NCT04377685
Testing for COVID-19 Infection in Asymptomatic Persons
NCT04345510
Rapid Detection of COVID-19 by Portable and Connected Biosensor
NCT04367142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be sampled for the tests at Day 1 and then monitored for symptoms and clinical data and additional test at Day 21.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental arm
These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.
COVID-19 diagnostic test
COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 diagnostic test
COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting at least one criterion for hospitalization:
* Respiratory failure and oxygenation
* Circulatory failure (systolic BP \< 90 mmHg)
* Neurological failure (confusion, drowsiness, altered consciousness)
* Polypathological terrain and co-morbidities (chronic respiratory failure, heart failure or cardiovascular pathology, renal failure, diabetes, immunosuppression, obesity, cirrhosis)
* Eligible for different sampling methods
* Beneficiary of a social insurance scheme or entitled person
Exclusion Criteria
* Minor patient
* Refusal to participate
* Patient under guardianship
* Patient under guardianship
* Pregnant or breastfeeding woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tourcoing Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre PATOZ, PharmD
Role: PRINCIPAL_INVESTIGATOR
CH TOURCOING
Barthelemy LAFONDESMURS, MD
Role: PRINCIPAL_INVESTIGATOR
CH TOURCOING
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH Tourcoing
Tourcoing, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RIPH_2020_6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.